These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32394228)

  • 1. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
    Juel CTB; Lund A; Andersen MM; Hansen CP; Storkholm JH; Rehfeld JF; van Hall G; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Diabetologia; 2020 Jul; 63(7):1285-1298. PubMed ID: 32394228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
    Rayner CK; Watson LE; Phillips LK; Lange K; Bound MJ; Grivell J; Wu T; Jones KL; Horowitz M; Ferrannini E; Tricò D; Frascerra S; Mari A; Natali A
    Diabetes Care; 2020 Aug; 43(8):1813-1821. PubMed ID: 32471908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.
    Hansen LS; Gasbjerg LS; Brønden A; Dalsgaard NB; Bahne E; Stensen S; Hellmann PH; Rehfeld JF; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2024 Aug; 191(2):192-203. PubMed ID: 39049802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.
    Whyte MB; Shojaee-Moradie F; Sharaf SE; Jackson NC; Fielding B; Hovorka R; Mendis J; Russell-Jones D; Umpleby AM
    J Clin Endocrinol Metab; 2019 Feb; 104(2):359-368. PubMed ID: 30215735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
    Ahrén B; Gautier JF; Berria R; Stager W; Aronson R; Bailey CJ
    Diabetes Obes Metab; 2014 Sep; 16(9):861-8. PubMed ID: 24641271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
    Jones KL; Rigda RS; Buttfield MDM; Hatzinikolas S; Pham HT; Marathe CS; Wu T; Lange K; Trahair LG; Rayner CK; Horowitz M
    Diabetes Obes Metab; 2019 May; 21(5):1158-1167. PubMed ID: 30623563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.
    Moore MC; Werner U; Smith MS; Farmer TD; Cherrington AD
    Am J Physiol Endocrinol Metab; 2013 Dec; 305(12):E1473-82. PubMed ID: 24148347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
    Lorenz M; Pfeiffer C; Steinsträsser A; Becker RH; Rütten H; Ruus P; Horowitz M
    Regul Pept; 2013 Aug; 185():1-8. PubMed ID: 23665027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
    Farngren J; Persson M; Ahrén B
    Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.